Myocarditis Following COVID-19 Vaccination : Cardiac Imaging Findings in 118 Studies
We reviewed the reported imaging findings of myocarditis in the literature following COVID-19 vaccination on cardiac imaging by a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), and Google Scholar. In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). The distribution of patients receiving vaccine dosage was investigated. On cardiac MR Imaging, late intravenous gadolinium enhancement (LGE) was observed mainly in the epicardial/subepicardial segments (90.8%, 318 of 350 enhancing segments), with the dominance of inferolateral segment and inferior walls. Pericardial effusion was reported in 13.1% of cases. The vast majority of patients (94%, 500 of 532) were discharged from the hospital except for 4 (0.7%) cases. Post-COVID-19 myocarditis was most commonly reported in symptomatic men after the second or third dose, with CMRI findings including LGE in 90.8% of inferior and inferolateral epicardial/subepicardial segments. Most cases were self-limited.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Tomography (Ann Arbor, Mich.) - 8(2022), 4 vom: 30. Juli, Seite 1959-1973 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keshavarz, Pedram [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AU0V1LM3JT |
|---|
| Anmerkungen: |
Date Completed 29.08.2022 Date Revised 13.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/tomography8040164 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345244850 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345244850 | ||
| 003 | DE-627 | ||
| 005 | 20231227130909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/tomography8040164 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM345244850 | ||
| 035 | |a (NLM)36006062 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keshavarz, Pedram |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myocarditis Following COVID-19 Vaccination |b Cardiac Imaging Findings in 118 Studies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We reviewed the reported imaging findings of myocarditis in the literature following COVID-19 vaccination on cardiac imaging by a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), and Google Scholar. In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). The distribution of patients receiving vaccine dosage was investigated. On cardiac MR Imaging, late intravenous gadolinium enhancement (LGE) was observed mainly in the epicardial/subepicardial segments (90.8%, 318 of 350 enhancing segments), with the dominance of inferolateral segment and inferior walls. Pericardial effusion was reported in 13.1% of cases. The vast majority of patients (94%, 500 of 532) were discharged from the hospital except for 4 (0.7%) cases. Post-COVID-19 myocarditis was most commonly reported in symptomatic men after the second or third dose, with CMRI findings including LGE in 90.8% of inferior and inferolateral epicardial/subepicardial segments. Most cases were self-limited | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Janssen/Johnson & Johnson | |
| 650 | 4 | |a Moderna | |
| 650 | 4 | |a Pfizer-BioNTech | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a myocarditis | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Contrast Media |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a Gadolinium |2 NLM | |
| 650 | 7 | |a AU0V1LM3JT |2 NLM | |
| 700 | 1 | |a Yazdanpanah, Fereshteh |e verfasserin |4 aut | |
| 700 | 1 | |a Emad, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Hajati, Azadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Nejati, Seyed Faraz |e verfasserin |4 aut | |
| 700 | 1 | |a Ebrahimian Sadabad, Faranak |e verfasserin |4 aut | |
| 700 | 1 | |a Azrumelashvili, Tamta |e verfasserin |4 aut | |
| 700 | 1 | |a Mizandari, Malkhaz |e verfasserin |4 aut | |
| 700 | 1 | |a Raman, Steven S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tomography (Ann Arbor, Mich.) |d 2015 |g 8(2022), 4 vom: 30. Juli, Seite 1959-1973 |w (DE-627)NLM25464306X |x 2379-139X |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:4 |g day:30 |g month:07 |g pages:1959-1973 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/tomography8040164 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 4 |b 30 |c 07 |h 1959-1973 | ||